XOMA Royalty Corporation (XOMA) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates strong financial performance with significant revenue and net income growth, robust royalty receipts, and strategic share buybacks. The Q&A reveals optimism about future royalty growth and strategic out-licensing opportunities, though management refrained from specific guidance. The company's legal confidence in the TREMFYA case adds a potential positive catalyst. Despite some uncertainties, the overall sentiment is positive, likely resulting in a stock price increase of 2% to 8% over the next two weeks.
Key Financial Performance
Total Portfolio Receipts Surpassed $50 million, including royalty receipts of $34 million, which grew 68% from fiscal year 2024. The growth was driven by VABYSMO and OJEMDA year-over-year increases as well as new contributions from MIPLYFFA following its approval for Niemann-Pick disease type C in late 2024.
Share Buybacks $16 million of capital was returned through opportunistic share buybacks in 2025, retiring more than 5% of common stock outstanding. This was part of a disciplined approach to capital deployment.
Unrestricted Cash Position Increased to over $80 million. This was achieved through nondilutive capital access and efficient portfolio expansion.
Full Year Total GAAP Income and Revenue $52.1 million compared with $28.5 million in 2024, representing significant growth. This was driven by increased royalty receipts and milestone payments.
G&A Expenses $36 million, a small increase compared with $34.5 million in 2024. The increase included $1.1 million associated with ongoing litigation against Janssen Biotech.
Full Year GAAP Net Income $31.7 million compared to a GAAP net loss of $13.8 million in 2024. This was influenced by accounting gains from acquisitions and other income items.
Cash Receipts from Royalties Approximately $34 million, which increased 68% compared to 2024. This was driven by VABYSMO and OJEMDA year-over-year increases and new contributions from MIPLYFFA.
Cash Milestone Payments Approximately $17 million from 6 programs achieving clinical, regulatory, and business development events.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Portfolio Assets: Added 22 assets to the XOMA royalty portfolio in 2025, including 2 platform technologies for potential out-licensing.
Commercial Programs: 7 commercially available programs, including OJEMDA and MIPLYFFA, with promising launches and potential geographic expansion.
Geographic Expansion: OJEMDA and MIPLYFFA submitted marketing authorizations in the EU in 2025. Ipsen submitted a marketing authorization in Japan for OJEMDA, triggering a $2 million milestone payment.
Revenue Growth: Total portfolio receipts surpassed $50 million, with royalty receipts growing 68% to $34 million from 2024.
Operational Efficiency: Achieved positive cash flow from operations and returned $16 million through share buybacks, retiring over 5% of common stock.
Portfolio Diversification: Doubled the number of assets in active development from 60 in 2023 to over 120 in 2025, with a sevenfold increase in commercially available and late-stage assets.
Strategic Transactions: Executed a revenue-sharing transaction with Takeda, adding rights to 9 development stage assets while reducing economic interest in mezagitamab.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Clinical Setbacks: Two Phase III studies, Rezolute's program for congenital hyperinsulinism and Gossamer Bio's seralutinib for pulmonary arterial hypertension, failed to show statistically significant differences at their respective thresholds relative to control arms. This poses a risk to the portfolio's expected milestones and royalty growth.
Litigation Costs: Ongoing litigation against Janssen Biotech for breach of contract and unjust enrichment related to Tremfya commercialization is incurring legal fees and professional service costs. The outcome is uncertain, and there is no assurance of recovery.
Economic Interest Reduction: Reduction in economic interest in Takeda's mezagitamab from mid-single-digit royalties to low single-digit royalties and reduced milestone potential could impact future revenue streams.
Loan Obligations: The Blue Owl loan, with a principal balance of $112.5 million, is self-amortizing and funded solely by VABYSMO receipts. Any underperformance in VABYSMO revenues could delay loan repayment and impact financial flexibility.
Regulatory and Clinical Risks: Several late-stage assets in the portfolio are awaiting regulatory approvals or clinical trial results. Delays or failures in these processes could impact future royalty and milestone payments.
Market and Launch Risks: The success of newly launched products like OJEMDA and MIPLYFFA depends on market adoption and geographic expansion. Any underperformance could affect royalty receipts.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Future Royalty Receipts: XOMA anticipates that royalty receipts alone will cover core operating costs by 2027, marking a significant inflection point in its business model.
Portfolio Expansion: The company plans to continue disciplined capital deployment to expand its portfolio breadth, focusing on high-quality therapeutic programs and innovative transactions.
Late-Stage Pipeline Catalysts: Key events expected in 2026 include top-line results from Rezolute's Phase III program for tumor hyperinsulinism, volixibat VISTAS study results in Q2, REC-4881 FDA engagement in H1, and additional data from AZ's TIGIT program in solid tumors.
Geographic Expansion: OJEMDA and MIPLYFFA are in early stages of promising launches with potential geographic expansion in the EU and Japan, supported by recent marketing authorizations and milestone payments.
Capital Allocation: XOMA aims to balance portfolio expansion with opportunistic share buybacks and debt reduction, maintaining a strong cash position of $83 million to support future investments.
Debt Management: The Blue Owl loan is expected to be fully repaid by 2030, potentially earlier, freeing up additional royalty receipts for XOMA.
Strategic Transactions: XOMA will continue leveraging innovative deal structures, such as revenue-sharing transactions and acquisitions, to add assets without significant capital risk.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Buyback Program: In 2025, XOMA Royalty returned $16 million of capital through opportunistic share buybacks, retiring more than 5% of its common stock outstanding. The company anticipates maintaining a disciplined approach to capital deployment, including continuing to reduce its equity base to increase future cash flow per share.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the growth prospects for royalty receipts over the next couple of years on approved products?
A:The growth prospects look strong, with VABYSMO being the largest contributor, showing double-digit constant currency growth last year. Other therapies like OJEMDA and MIPLYFFA are ramping up well, and pipeline developments could further enhance growth. However, no specific guidance was provided.
Q:Can you provide more color on the TREMFYA economic opportunity and your confidence in being justified royalties?
A:The company and its legal advisers are confident in the breach claim related to TREMFYA, stemming from a 2003 agreement with MorphoSys. Historically, similar relationships have had royalty rates in the low single digits. The outcome of the litigation is uncertain, but the company views it as a high-probability success case.
Q:Could you share more details about the two platform technologies you are considering out-licensing?
A:The two technologies obtained from Generation Bio include ctLNP (cell-specific LNP delivery) and iqDNA (DNA delivery to the nucleus). ctLNP has promising nonhuman primate data, and iqDNA is in earlier stages. The company plans to license these technologies to third parties for royalties and milestones without investing R&D dollars.
Q:How do you prioritize between returning capital to shareholders and doing new deals?
A:The company balances between reducing the equity base to increase free cash flow per share and diversifying the portfolio through external opportunities. They prioritize internal investments but remain opportunistic with external deals.
Q:What is your view on the opportunity for Rezolute's program ersodetug?
A:The consensus estimates for the two indications combined approach $1 billion, with a 60-40 split between congenital and tumor hyperinsulinism. The tumor market may present a larger opportunity over time due to patient population and weight-based dosing.
Q:How should we think about the cadence of new deal activity and the mix between smaller, earlier-stage deals and larger, derisked opportunities?
A:The company focuses on quality over quantity and does not set specific targets for deal cadence or capital deployment. They are opportunistic and consider assets across all stages, aiming to maximize cash flow and diversify the portfolio.
Q:What led to the amendment of the Takeda deal?
A:The amendment was driven by the company's strategy to diversify its revenue and portfolio stream. They approached Takeda with the idea of a shared royalty transaction, leveraging the value of mezagitamab and other assets in Takeda's portfolio.
Q:How do you see the capital structure evolving over the next year?
A:The company may consider optimizing its capital structure by addressing the preferred equity, which is less tax-advantaged, while maintaining the Blue Owl loan. They aim to explore lower-cost, tax-advantaged financing options.
Q:Review of Unclear Management Responses
A:Management avoided providing specific guidance on the growth prospects for royalty receipts over the next couple of years, despite expressing optimism. Additionally, while discussing the TREMFYA litigation, they acknowledged the uncertainty of the outcome, using cautious language like 'it could go either way.'
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Blue Owl
MIPLYFFA
OJEMDA
Owl loan
Phase II
Phase III
Takeda
acquisition
balance
capital
cash flow
company
development
digit royalty
equity
income
interest
line
milestone payment
number
portfolio
program
result
right
risk
royalty milestone
royalty receipt
sale
share
stage asset
statement
study
today
transaction
value
XOMA Transcript
Boyd Group Services Inc. (BYD:CA) Q4 2025 Earnings Call Transcript
Positive3-18
The earnings call reveals strong financial performance with strategic initiatives like Project 360, expected margin improvements, and positive integration of Joe Hudson's. The CEO's optimism about market share gains and growth in scanning services further supports a positive outlook. While some uncertainties remain, such as the impact of paint rebates and procurement savings, the overall sentiment is positive. The Q&A session highlighted management's confidence in overcoming challenges, aligning with insurance partners, and capitalizing on market opportunities, suggesting a likely stock price increase in the short term.
XOMA Royalty Corporation (XOMA) Q4 2025 Earnings Call Transcript
Positive3-18
The earnings call summary indicates strong financial performance with significant revenue and net income growth, robust royalty receipts, and strategic share buybacks. The Q&A reveals optimism about future royalty growth and strategic out-licensing opportunities, though management refrained from specific guidance. The company's legal confidence in the TREMFYA case adds a potential positive catalyst. Despite some uncertainties, the overall sentiment is positive, likely resulting in a stock price increase of 2% to 8% over the next two weeks.
XOMA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
